Sangamo Therapeutics (NASDAQ:SGMO) Insider Gregory Davis Sells 69,827 Shares

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) insider Gregory Davis sold 69,827 shares of Sangamo Therapeutics stock in a transaction on Wednesday, April 22nd. The stock was sold at an average price of $0.25, for a total transaction of $17,456.75. Following the completion of the transaction, the insider directly owned 115,284 shares of the company’s stock, valued at $28,821. The trade was a 37.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Sangamo Therapeutics Stock Down 1.1%

Sangamo Therapeutics stock opened at $0.26 on Friday. The company’s 50-day moving average price is $0.34 and its 200-day moving average price is $0.44. The company has a market cap of $105.64 million, a PE ratio of -0.58 and a beta of 1.49. Sangamo Therapeutics, Inc. has a twelve month low of $0.21 and a twelve month high of $0.84.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings results on Monday, March 30th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.12). The business had revenue of $14.23 million during the quarter, compared to the consensus estimate of $40.25 million. Sangamo Therapeutics had a negative net margin of 310.81% and a negative return on equity of 2,662.06%. As a group, sell-side analysts expect that Sangamo Therapeutics, Inc. will post -0.17 earnings per share for the current fiscal year.

Institutional Trading of Sangamo Therapeutics

Several institutional investors have recently added to or reduced their stakes in SGMO. World Investment Advisors boosted its position in shares of Sangamo Therapeutics by 88.5% during the third quarter. World Investment Advisors now owns 42,611 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 20,000 shares during the period. Cetera Investment Advisers purchased a new stake in shares of Sangamo Therapeutics in the fourth quarter worth approximately $31,000. XTX Topco Ltd purchased a new stake in shares of Sangamo Therapeutics in the second quarter worth approximately $41,000. Engineers Gate Manager LP lifted its stake in shares of Sangamo Therapeutics by 101.7% during the 2nd quarter. Engineers Gate Manager LP now owns 87,425 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 44,078 shares during the last quarter. Finally, State of Wyoming bought a new stake in shares of Sangamo Therapeutics during the 4th quarter worth approximately $47,000. Institutional investors own 56.92% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. Wall Street Zen cut Sangamo Therapeutics to a “strong sell” rating in a report on Saturday, January 31st. Zacks Research lowered Sangamo Therapeutics from a “hold” rating to a “strong sell” rating in a report on Thursday, April 16th. Weiss Ratings restated a “sell (e+)” rating on shares of Sangamo Therapeutics in a research report on Thursday, January 22nd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Sangamo Therapeutics in a research note on Tuesday, February 10th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Sangamo Therapeutics presently has an average rating of “Reduce” and a consensus target price of $5.50.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc is a clinical-stage biotechnology company headquartered in Brisbane, California, that specializes in the development of genomic therapies based on its proprietary zinc finger nuclease (ZFN) technology. Founded in 1995, Sangamo pioneered ZFN-based genome editing to precisely alter DNA sequences for the treatment of serious genetic and rare diseases. The company’s platform encompasses in vivo genome editing, ex vivo cell therapy, and genome regulation approaches, with a focus on durable therapeutic effects through permanent genetic modification or sustained gene expression control.

Through its genome editing programs, Sangamo is advancing multiple product candidates into clinical trials for conditions such as hemophilia A and B, mucopolysaccharidosis types I and II, and lysosomal storage disorders.